Clinical Trials

Breast Neoplasms

NCT05385705 2025-09-22

A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020

2 enrolled

Breast Neoplasms

NCT06239467 2025-09-09

PIKture-01

Phase 1 Recruiting

200 enrolled

Breast Neoplasms

NCT06886659 2025-07-22

A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche)

80 enrolled

Breast Diseases, Breast Neoplasms

NCT03767335 2025-06-26

B-PRECISE-01

62 enrolled 18 charts

Phase 1 Active not recruiting

Breast Neoplasms

NCT00393783 2025-06-05

Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity

13 enrolled

Phase 1 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT04188548 2025-06-04

EMBER

500 enrolled

BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

BreastDermatologicLymphoid

17 enrolled

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT01649271 2025-02-11

Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.

13 enrolled 11 charts

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT00950742 2025-02-10

Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.

18 enrolled 14 charts

Breast Neoplasms

NCT01921335 2024-11-06

ARRY-380 + Trastuzuamab for Breast w/ Brain Mets

41 enrolled

Breast Neoplasms

NCT04120246 2024-07-10

Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer

Phase 1 Suspended

24 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT00963547 2024-06-04

MK-2206-015

33 enrolled 13 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms

NCT05143970 2024-03-20

CHANCES

Phase 1 Unknown

27 enrolled

Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT06162559 2024-01-11

TRAIN-4

Phase 1 Recruiting

30 enrolled

Breast Neoplasms

NCT01300962 2023-12-04

Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer

47 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & NeckThoracic

5 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04367090 2023-09-18

Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer

97 enrolled

Breast Neoplasms

NCT02649686 2023-08-04

Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab

15 enrolled

Breast Neoplasms

NCT00251433 2023-03-31

GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer

53 enrolled

Breast Neoplasms

NCT05765357 2023-03-13

Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers

89 enrolled

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT02627274 2022-11-22

A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

134 enrolled

BreastHead & Neck

Breast Neoplasms, Head and Neck Neoplasms

NCT00807859 2022-11-08

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

65 enrolled

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT03364348 2022-10-19

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

18 enrolled 17 charts

Breast Neoplasms

NCT02569489 2022-07-18

Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms

NCT02562378 2022-02-23

THELMA

15 enrolled 39 charts

Breast Neoplasms

NCT03135171 2021-09-10

Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab

11 enrolled

Breast Neoplasms

NCT02167854 2021-07-09

Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer

23 enrolled

Breast Neoplasms

NCT04905667 2021-05-27

Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®

87 enrolled

Breast Neoplasms

NCT00788931 2020-12-19

A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer

15 enrolled

Breast Neoplasms

NCT02152943 2020-12-19

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

37 enrolled

Breast Neoplasms

NCT03846583 2020-10-23

Tucatinib + Abemaciclib + Herceptin for HER2+ MBC

Phase 1 Withdrawn

Breast Neoplasms

NCT00367471 2020-09-09

Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.

31 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT00085020 2020-08-03

GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu

13 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT02025192 2020-06-04

A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer

60 enrolled

Breast Neoplasms

NCT03680560 2020-03-31

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

6 enrolled

BreastGastrointestinal

Breast Neoplasms, Carcinoma, Adenoid Cystic, Stomach Neoplasms

NCT02605915 2020-02-05

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

98 enrolled

Breast Neoplasms

NCT04175171 2019-12-18

Clinical Trial of Comparative Study of GB221 Pharmacokinetics

32 enrolled

Breast Neoplasms

NCT01434303 2019-05-20

Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only

37 enrolled

Breast Neoplasms

NCT03013881 2019-04-03

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UB-921 in Healthy Volunteers

18 enrolled

Breast Neoplasms

NCT02060253 2018-06-14

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

9 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT02738970 2018-06-12

A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)

88 enrolled

Breast Neoplasms

NCT02598427 2018-02-28

Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer

1 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT01304797 2017-01-06

Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer

Phase 1 Unknown

75 enrolled